Brief: Merus Receives FDA Extension Of PDUFA For Zenocutuzumab
05/11/2024 11:40
Nov 5 (Reuters) - Merus NV 2GH.F :
* MERUS RECEIVES FDA EXTENSION OF PDUFA FOR ZENOCUTUZUMAB
* MERUS NV - FDA EXTENDS PDUFA GOAL DATE TO FEBRUARY 4, 2025
Source text: ID:nGNX2W9CpF
Further company coverage: 2GH.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab